NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2003
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
7
Data completeness
7/8 — Comprehensive
ACULAR LS (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. Approved for postoperative pain, postoperative anterior chamber inflammation, cataracts. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACULAR LS is a ketorolac tromethamine ophthalmic solution, a nonsteroidal anti-inflammatory drug (NSAID) administered as eye drops. It works by inhibiting prostaglandin biosynthesis to reduce pain and inflammation. The product is indicated for postoperative pain and anterior chamber inflammation following cataract surgery, as well as allergic conjunctivitis and rhinitis.
$0.024BPart D
LOE Approaching1.6 years to LOEWith LOE approaching in 1.6 years and minimal Part D spending ($24K in 2023), the brand team is entering a wind-down phase with limited growth opportunities and likely reduced headcount.
Mechanism of Action
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Worked on ACULAR LS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.